Short-term effect of HAART on blood pressure in HIV-infected individuals

HIV Clinical Trials

Volumn 9, Issue 1, 2008, Pages 52-60

  Grandominico, Jodi M ^a   Fichtenbaum, Carl J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Blood pressure; HIV; Hypertension

Indexed keywords

ATAZANAVIR; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NUCLEOSIDE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TIPRANAVIR;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING; SHORT COURSE THERAPY; STATISTICAL ANALYSIS; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD PRESSURE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEASE INHIBITORS;

EID: 38949121641     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0901-52     Document Type: Article

References (26)

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280(17):1497-1503.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860.
3. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. Top HIV Med. 2005;13(1):16-23.
4. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
5. Glesby MJ. Coronary heart disease in HIV-infected patients. Curr HIV/AIDS Rep. 2005;2(2):68-73.
6. Hurwitz BE, Klimas NG, Llabre MM, et al. HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk: role of protease inhibitor exposure. Cardiovasc Toxicol. 2004;4(3):303-316.
7. Behrens GM, Meyer-Olson D, Stoll M, Schmidt RE. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS. 2003;17(Suppl 1):S149-154.
8. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53(1):10-14.
9. Leow MK, Addy CL, Mantzoros CS. Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab. 2003;88(5):1961-1976.
10. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med. 2005;6(2):99-106.
11. Manfredi R. HIV disease and advanced age: an increasing therapeutic challenge. Drugs Aging. 2002;19(9):647-669.
12. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
13. Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003;22(12):731-736.
14. Aoun S, Ramos E. Hypertension in the HIV-infected patient. Curr Hypertens Rep. 2000;2(5):478-481.
15. Cattelan AM, Trevenzoli M, Naso A, Meneghetti F, Cadrobbi P. Severe hypertension and renal atrophy associated with indinavir. Clin Infect Dis. 2000;30(3):619-621.
16. Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A, Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials. 2003;4(6):411-416.
17. Gazzaruso C, Bruno R, Garzaniti A, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003;21(7):1377-1382.
18. Khurana V, de la Fuente M, Bradley TP. Hypertensive crisis secondary to phenylpropanolamine interacting with triple-drug therapy for HIV prophylaxis. Am J Med. 1999;106(1):118-119.
19. Mattana J, Siegal FP, Sankaran RT, Singhal PC. Absence of age-related increase in systolic blood pressure in ambulatory patients with HIV infection. Am J Med Sci. 1999;317(4):232-237.
20. Seaberg EC, Munoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19(9):953-960.
21. Hewitt RG, Thompson WM, Chu A, Hernandez F, Shelton MJ. Indinavir, not nelfinavir, is associated with systemic hypertension when compared to no protease inhibitor therapy [abstract 658]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health; 2001.
22. Shankar SS, Dube MP, Gorski JC, Klaunig JE, Steinberg HO. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J. 2005;150:933e1-933e7.
23. Messerili FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370:591-603.
24. Crane HM, Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active retroviral therapy. AIDS. 2006;20:1019-1026.
25. Stein JH, Cotter BR, Parker RA, Murphy RL, Fichtenbaum CJ, Currier JS, et al. Antiretroviral therapy improves endothelial function in individuals with human immunodeficiency virus infection: a prospective, randomized multicenter trial (Adult AIDS Clinical Trials Group Study A5152s). Presented at the American Heart Association Scientific Sessions; November 13-16, 2005; Dallas, Texas. Abstract 9606.
26. Pickering TG, Hall JE, Appel IJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697-716.